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Summary
Attitudes about disclosing the identities of family mem-
bers to a physician to ensure diffusion of genetic risk
information within affected families were examined in
a questionnaire study of Danish patients with a1-anti-
trypsin deficiency (A1AD), their relatives, and a control
group of Danish citizens. The questionnaires were re-
turned by 1,761 (82%) of 2,146 recipients; 1,609 (75%)
agreed to participate and completed the questionnaire.
Only 2.8% objected to disclosing the identity of chil-
dren, 9.1% objected to disclosing the identity of parents,
and 6.7% objected to disclosing the identity of siblings.
When genetic tests are offered to a sister, 75.4% of
screened individuals with severe A1AD (phenotype
“piZ”) and 66.8% of piZ probands thought that the
physician should say who is ill. Important reasons for
informing a sister at risk were, for 58%, the opportunity
to prevent disease and, for 41% of piZ-probands, the
opportunity to maintain openness in the family and to
avoid uncertainty. Stepwise logistic regression of back-
ground variables showed that relatives were those for
whom most respondents approved the disclosure of the
parents’ and siblings’ identities to enable the physician
to examine them for the presence of A1AD.Womenwere
less prone to disclose the identity of siblings. The results
indicate that the genetic counselor should inquire about
relatives’ identities, to ensure that they are properly in-
formed about the known risk of severe genetic disorder,
such as A1AD, for which disability can be prevented by
a change of lifestyle or by careful management. Disease
prevention is essential, but openness and avoidance of
uncertainty in affected families are also important. Our
findings imply that fully informing all relatives about the
disorder and about who is actually ill should be the
principal rule.
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Introduction
Detection of genes responsible for many common and
serious diseases, such as breast cancer (Miki et al. 1994),
raises concern about ethical issues that include respect
for the individual’s autonomy and privacy (Caplan
1993; Wilcke 1998) and professional disclosure of ge-
netic information in families (American Society of Hu-
man Genetics [ASHG] Social Issues Subcommittee on
Familial Disclosure 1998). Specific genetic data reveal
information not only about the specific person examined
but also about the person’s relatives and future children,
who may either be sick or carry the trait.
It is generally accepted that it is a doctor’s duty to
inform and warn patients about reasonably foreseeable
dangers arising from the use of prescribed drugs, devices,
and diagnostic procedures (Berg and Hirsh 1980). It has
also been stated (e.g., in the Tarasoff case) that physi-
cians and psychotherapists must warn identifiable third
parties of an impending danger identified during the
course of treating a patient (Hirsh 1975).
In the Safer case, which concerned multiple polyposis,
a U.S. court held that the physician should directly warn
those “known to be at risk of avoidable harm from a
genetically transmissible condition,” irrespective of po-
tential conflicts between the duty to warn and the ob-
ligation of confidentiality—provided that certain con-
ditions are met (ASHG Social Issues Subcommittee on
Familial Disclosure 1998). In the Pate case, the highest
state court in Florida held that the duty to warn was
satisfied if the physician warned the patient that the con-
dition (thyroid carcinoma) could be transmitted genet-
ically (McAbee et al. 1998; Merz et al. 1998).
The fact that pulmonary insufficiency due to a1-
antitrypsin deficiency (A1AD) can be prevented or re-
duced by an individual’s refraining from smoking has
been the reason for a very active approach and infor-
mation policy in Denmark, since 1978, toward relatives
who are at risk of having A1AD (Wilcke 1998). The
aim of the present study was to evaluate professional
disclosure of genetic information about A1AD to fam-
ilies, which implies the use of information about rela-
tives’ identity. In a questionnaire study, we examined the
attitudes of patients with A1AD, their relatives, and a
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group of controls toward disclosing the identity of rel-
atives to a physician so as to ensure diffusion of precise
genetic risk information within the families.
A1AD
Severe A1AD (phenotype piZ (genotype ZZ) and a
few other rare variants) is an autosomal recessive single-
gene disorder that may cause serious pulmonary im-
pairment in young and middle-aged adults. In the Scan-
dinavian population, 1/1,600 are phenotype piZ, and
A1AD is more common than cystic fibrosis (1/4,700
Danes) (Nielsen et al. 1988). However, in contrast to
cystic fibrosis, not all individuals affected with A1AD
(type piZ) become ill, because those who have never been
smokers seldom develop lung disease (Wu and Eriksson
1988). Smokers with phenotype piZ have a very high
risk of developing severe dyspnea at age ∼35–40 years
and of premature death due to progressive emphysema
(Larsson 1978). Median survival is 50 years for smokers,
whereas the survival of individuals with piZ who were
never smokers is no different from that of the normal
population (Seersholm and Kok-Jensen 1995). Apart
from refraining from smoking (Seersholm et al. 1994),
other treatments for A1AD are of dubious effectiveness.
a1-Antitrypsin augmentation therapy has never been
evaluated in a randomized clinical trial. Specific diag-
nosis based on blood samples is valid and is easy and
acceptable for both carriers and affecteds (Buist 1990).
Population screening for A1AD has been done in sev-
eral countries, and the adverse psychosocial effects of
screening all newborns for A1AD have been extensively
described by a Swedish group (Thelin et al. 1985;
McNeil et al. 1986). To our knowledge, general screen-
ing for A1AD is not done in any country at present.
The Danish A1AD Register
In Denmark, when a person with A1AD (piZ) has
been identified, that person’s data are reported to a cen-
tral register after informed consent has been given. Soon
thereafter, the proband receives a personal letter con-
taining brief information about the deficiency and the
risk for relatives of inheriting A1AD and developing lung
disease (pulmonary emphysema). The proband is asked
to supply the register with data on relatives with 1%
risk of piZ (names, dates of birth, and addresses of par-
ents, siblings, cousins, and children). The letter empha-
sizes that this information is given to the register on a
voluntary basis and that the data are confidential. It also
emphasizes that the purpose of the request is to inform
the relatives by letter, provided consent is given, about
their risk and about the consequences of piZ and to offer
relatives easy access to further information and exami-
nation, free of charge, including blood tests for A1AD.
The identity of the proband is disclosed to relatives on
request if consent to this has been given. In our expe-
rience this procedure accommodates individual wishes
and allows for passing on information to relatives. Some
probands choose to let the register approach relatives
directly, whereas others distribute a copy of the A1AD
register’s general information to relatives without in-
volving a physician.
Material and Methods
Questionnaire and Enclosed Letter of Introduction
The letter of introduction we used (available in English
translation on request) described A1AD, the hereditary
nature of A1AD, consequences of having A1AD, options
for prevention of disease (refrain from smoking), and
the purpose of the study, and it stated that participation
was voluntary and anonymous. The letter described a
simple hypothetical situation for a 35-year-old woman,
Nina, who smokes, becomes more and more short of
breath, and is finally diagnosed as having A1AD. Par-
ticipants were asked to answer the questionnaire as if
they were Nina.
The present paper focused on two small vignettes,
with Nina as proband, in which participants were asked:
“Should Nina disclose the identities of her parents, sib-
lings, and children, to enable her physician to offer them
testing for A1AD?” (fig. 1), and “Should the physician
tell Nina’s brothers and sisters who is ill when offering
them testing for A1AD?” (fig. 2). Possible answers were
categorized as “definitely no,” “perhaps no,” “perhaps
yes,” or “definitely yes.” Furthermore, respondents were
asked to select a maximum of 3 of 11 statements related
to the question, “Do you think that Nina’s sister should
be informed about her risk of A1AD?” (the 11 state-
ments are shown in fig. 3).
Study Population
The questionnaire was sent to 2,146 subjects belong-
ing to 6 groups: (1) the “control” group: individuals
randomly selected from the Danish population through
the National Register of Danish citizens; (2) the “M”
group: piM relatives identified by family screening; (3)
the “MZ” group: piMZ relatives identified by family
screening; (4) the “no type” group: nonexamined rela-
tives with 11% risk of piZ, who had not answered at
least one written inquiry from the register; (5) the “Z-
screened” group: piZ relatives identified by family
screening; and (6) the “Z-proband” group: piZ pro-
bands diagnosed because of lung symptoms.
For all piM and piMZ subjects, the phenotypes were
determined by isoelectric focusing (Buist 1990). For the
piZ subjects, phenotype was determined by isoelectric
focusing or by a1-antitrypsin blood level !11 mmol/l.
When possible, 400 subjects with known addresses were
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Figure 1 Responses to the question, Should Nina disclose the
identities of her parents, siblings, and children, to enable her physician
to offer them testing for A1AD? * , ** .P ! .01 P ! .005
Figure 2 Responses to the question, Should the physician tell
Nina’s brothers and sisters who is ill when offering them testing for
A1AD? * , ** .P ! .01 P ! .005
randomly drawn from each group in the register. For
groups of !400 individuals, the questionnaire was sent
to all subjects in the group (i.e., the Z-screened, Z-pro-
band, and no-type groups).
The questionnaire was sent by mail in July 1996, and
reminders were sent to nonresponders after 2 and 4
months. Questionnaires were answered and analyzed
anonymously. Table 1 gives demographic data and re-
sponse rates for the different groups. The apparently
higher number of persons with children in the M, Z-
screened, and Z-proband groups was not significant af-
ter adjustment by logistic regression for the older age in
these groups.
Statistical Analysis
For each group, the response to each question was
compared with the control group by univariate analysis.
One-tailed P values were computed by Fisher’s exact
test, and P values !.01 were judged significant.
To analyze whether responses were related to factors
pertaining to the respondents’ personal backgrounds, we
performed multivariate analysis with phenotype/group
and demographic data as independent variables and with
attitude responses as dependent variables in a stepwise
logistic regression model (backward likelihood ratio lo-
gistic regression model, in the computer program SPSS
6.1 1993).
Results
The questionnaire was returned by 1,761 individuals
(82%), of whom 1,609 (75%) agreed to participate and
completed the questionnaire. Figure 1 shows that, in
total, only 2.8% (44 subjects) objected to informing the
physician about their children’s identity, and most be-
longed to the control group (24 of 44 who answered
“definitely no” or “perhaps no” to the question). Re-
garding parents and siblings, a few more respondents
objected to informing the physician—namely, 9.1% and
6.7%, respectively. Again the control group dominated:
82 of 146 objected with respect to parents, and 61 of
107 objected with respect to siblings.
Forty-three percent, 43%, and 35% felt that the phy-
sician ought to get consent from the proband before
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Figure 3 Respondents were asked to select a maximum of 3 of
11 statements relating to the question, Do you think that Nina’s sister
should be told about her risk for A1AD? The precise wording of
possible answers were (1) Yes, because the sister is herself at risk of
having A1AD, (2) Yes, because the sister’s children are at risk of having
A1AD, (3) Yes, because the lung disease can be prevented, (4) Yes, to
maintain openness in the family, (5) Yes, to escape uncertainty, (6)
Yes, to enable the sister to decide on her own whether she wants testing,
(7) Yes, but only if the sister smokes, (8) No, one cannot stop smoking
anyway, (9) No, I don’t want to force information on her, which she
may not want, (10) No, because she may encounter problems when
taking out life insurance, and (11) Other (please write):
_____________. * , ** .P ! .01 P ! .005
approaching parents, children, and siblings, respectively.
In the control group, 52% felt that consent was neces-
sary before parents were approached, compared with
26%–42% in the other groups. In all, 54.8%—and sig-
nificantly more among the Z-screened (75.4%) and Z-
proband (66.1%) groups—agreed that the physician
ought to disclose who is ill when offering testing to a
sister (fig. 2).
Figure 3 shows reasons for informing or not informing
Nina’s sister. In all, 1.5% gave only “no” responses,
3.3% gave both “no” and “yes” responses, 93.0% gave
only “yes” responses, and 2.2% did not select any of
these responses. In all, 58% selected “yes, because the
lung disease can be prevented,” highest in the no-type
group (66%) and lowest in the piZ groups (48%). In
all, 35% chose “yes, to keep openness in the family”
and/or “yes, to escape uncertainty,” highest for the Z-
proband group (41%) and lowest for the no-type group
(29%).
The stepwise logistic regression analysis showed that
the phenotype/group of the respondents was significantly
related ( ) to their attitudes about disclosure ofP ! .05
the identity of parents and siblings. Sex of respondents
was shown to be significantly related to disclosure of
the identity of siblings. This means that tested relatives
M, MZ, and Z-screened were those for whom most re-
spondents approved the disclosure of the parents’ and
siblings’ identities to the physician. Furthermore, women
were less prone to disclose the identity of siblings.
Discussion
In all study groups there was a strong consensus that
the proband ought to disclose the identity of parents
(fig. 1a), siblings (fig. 1b), and especially children (fig.
1c), to enable the physician to offer them examination
for A1AD. The results indicate that the genetic counselor
should actively try to ensure that relatives are ap-
proached and informed about the known risk of a severe
genetic disorder, such as A1AD, in which disability can
be prevented by a change of lifestyle (e.g., smoking ces-
sation) or by careful management. This is in line with
results from tests for other genetic diseases with modi-
fiable outcome (Bratt et al. 1997; Andersen et al. 1998).
Differences in attitude between patients (Z-probands),
their relatives (with or without the disorder), and the
control group were modest for most questions, although
statistically significant for some. For all questions, the
control group was most hesitant to disclose the identities
of relatives to the physician and to inform relatives about
their risk for A1AD.
The results suggest that attitudes about transmission
of genetic information reflect individual experience and
self-knowledge and that these attitudes vary, depending
on whether the respondent is the ill proband, the pro-
band’s parent, the proband’s descendant, or someone
who has never heard of A1AD. With this in mind, these
various groups will be discussed separately.
Among probands, 71% of piZ (Z-screened and Z-
proband) respondents thought that the physician ought
to tell the relatives who was ill (fig. 2). This was highly
confidential information about themselves and their dis-
ease. This lack of concern about one’s own right to pri-
vacy (Wilcke 1998) may be explained by the need of
sick persons for support from family and friends. Qual-
itative studies of hereditary intestinal cancer (Michie et
al. 1996) and A1AD (the interview part of the present
study) suggested that, to achieve such family support, it
is crucial to maintain openness about the disease in the
family and to avoid obfuscation, myths, and uncertainty
among relatives. In agreement with this, 41% of the
probands in the present study selected openness and
avoidance of uncertainty (fig. 3) as important reasons
to inform a sister. Information about personal disease is
usually considered highly confidential, and this was re-
flected in the attitudes of the “less experienced,” when
far fewer in the control group (55% compared with 75%
in the Z-screened group) approved physician disclosure
of who was ill (fig. 2).
Among probands, 80%–92% definitely approved dis-
closure of children’s and siblings’ identities (fig. 1). The
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Table 1
Baseline Demographic Characteristics
Characteristic of Subgroup
Control
(n = 847)
piM
(n = 400)
piMZ
(n = 400)
piZ-screened
(n = 165)
piZ-proband
(n = 133)
No Type
(n = 201)
Total
(n = 2,146)
No. of men (%) 424 (50%) 172 (43%) 194 (48%) 77 (47%) 76 (57%) 125 (62%) 1,068 (50%)
Age in years (mean  SD) 43.9  15 44.3  14 43.1  14 48.3  13 49.6  10 46.7  12 44.8  14
Respondents (%):
Full response 577 (68.1%) 309 (77.3%) 341 (85.3%) 135 (81.8%) 119 (89.5%) 128 (63.7%) 1,609 (75%)
Chose not to participate 82 (9.7%) 22 (5.5%) 18 (4.5) 6 (3.6%) 4 (3.0%) 6 (3.0%) 152 (7.1%)
School education (%):
Attending school 1 1 1 ) ) 1
Attended school:
17 years 19 21 21 25 36** 26
8–9 years 18 20 18 21 21 20
19 years 58 53 27 50 39* 49
Other 4 6 3 4 4 3
Employment (%):
Employed 65 71 71 53 29** 73
Retired 18 17 15 37** 60** 12
Unemployed 5 3 7 5 3 8
Student 7 4 4 3 2 4
Other 5 5 3 3 3 2
Living (%):
Alone 15 14 17 22 19 13
With wife/husband/partner 70 75 72 70 71 79
With children 5 7 8 6 7 6
With siblings 1 ) 1 ) ) 1
Other 8 4* 2** 2* 4 2*
Has children (%):
No 30 20** 27 19** 19* 20
Yes 70 80** 73 81** 81* 80
Smoking status (%):
Smoke daily 33 35 35 7** 8** 48*
Smoke, not daily 9 5 6 5 2* 2*
Stopped 2 years ago 1 2 4 8** 2 2
Stopped 12 years ago 22 26 18 53** 71** 20
Never smoked 35 33 37 28 18** 28
Self-reported health status (%):
Very good 42 45 45 25** 8** 38
Good 38 36 36 27* 15** 45
OK 17 17 16 28* 40** 17
Bad 3 1 3 11** 25** )
Very bad 0 1 ) 8** 12** )
Meets family (%):
Daily 22 22 15* 20 16 14
1–2#/week 36 40 49** 33 36 31
1–2#/mo 33 32 29 33 34 45
Less often 8 7 7 13 11 11
Never 0 0 0 1 3 )
Meets friends (%):
Daily 23 17 19 18 9** 16
1–2#/week 38 40 40 41 42 39
1–2#/mo 33 37 35 33 38 39
Less often 5 5 6 7 12 6
Never 0 0 0 1 0 0
NOTE.–Fisher’s exact test, with control group as reference. * , ** .P ! .01 P ! .005
probands were more moderate with respect to disclosure
of parents’ identities. This reluctance toward parents was
also found in the interview part of the study (data not
shown), and reasons given by the interviewees were that
parents must be piMZ (at least if they were healthy and
smokers) and that they were older and had less oppor-
tunity to change a possible course of disease—or, as one
respondent put it, “It’s too late anyway.” Another reason
may be that affected persons want to save their parents
from possible feelings of guilt about passing on the
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A1AD gene to their children. Some interviewees em-
phasized that parents ought sometimes to know, both
to avoid uncertainty as to what might be wrong with
their children and to maintain openness within the fam-
ily. This indicates that the consequences of informing
parents compared with other relatives differ, and this
suggests that it may be reasonable to leave the informing
of parents to be handled as an internal family matter.
The difference in attitude toward parents, siblings, and
children has also been found in studies of hereditary
cancer (Bratt et al. 1997).
A substantial number (35%–43%) of respondents
found that the physician ought to get consent from the
proband before approaching relatives. Consent seemed
especially necessary before parents are approached (43%
overall and 52% in the control group). However, the
majority in the affected groups (i.e., M, MZ, Z-screened,
Z-proband, and no-type groups) felt that the proband’s
consent remained irrelevant, even after correction for
those responding “no” to the “disclose information”
and “get proband’s consent” questions. In an American
study of first-degree relatives of women with breast/
ovarian cancer, 56%–57% felt that the proband’s con-
sent should be required for the immediate family to re-
ceive similar risk information (Benkendorf et al. 1997).
These moderate differences between studies may be ex-
plained by the different options to escape disease in
A1AD and breast/ovarian cancer (i.e., avoid smoking vs.
mastectomy/ovariectomy) and by cultural and educa-
tional differences between respondents, as shown by
Benkendorf et al. (1997).
In this context, it may be mentioned that Denmark is
situated in the northern part of western Europe and that
the Danish state health insurance is based on the Eu-
ropean health care model, which strives for equal access
to health services for all. Health insurance is compulsory,
is paid through taxes, and offers free health care to all,
irrespective of risks, faults, employment, and economic
and social status. In general, the Danish medical practice
is nonpaternalistic. The interview parts of the present
A1AD study and other studies (Thomsen et al. 1993)
show that Danes expect to be involved in decision mak-
ing and expect full information from the physician, to
enable them to decide on their own.
Relatives at risk often have the role of observer and/
or helper in families affected by chronic disease (Bury
1988; Robinson 1988). Several studies have shown that
it is a huge strain to witness very close relatives, espe-
cially parents, suffering from a chronic disease and be-
coming more and more disabled (Turk 1979; Strauss et
al. 1984). It has also been shown (e.g., for family mem-
bers of patients with Huntington disease) that it is often
a great relief to undergo genetic testing and so obtain
knowledge about one’s own risk (Tibben et al. 1993).
The Huntington disease test result itself, whether favor-
able or not, does indeed increase the sense of control
over the future. Thus, merely getting an answer, whether
bad or good, increased the wellbeing of persons at risk
of Huntington disease, compared with persons who did
not undergo the predictive test (Hayes 1992; Wiggins et
al. 1992). Surprisingly, it was also found that both
favorable (Bloch et al. 1992) and unfavorable results
caused personal and family dislocation, especially for
those who had made irreversible decisions, such as not
having children and running up large debts, on the basis
of their belief that they would develop Huntington dis-
ease (Huggins et al. 1992). Other explanations given for
adverse reactions among those found not to be carriers
were “survivor guilt” and a sudden change in their un-
derstanding of themselves and in their relationships with
their families and futures. Similar “functional pessi-
mism” was found after a new genetic test indicating an
extremely low risk in family members who had under-
gone bowel screening procedures regularly, for a long
time, because of familial adenomatous polyposis (Michie
et al. 1996). Long periods of uncertainty causing im-
proper identity and family bonds among individuals
with genetic risk can be avoided by facilitating the trans-
mission of genetic risk information within families and
by reducing diagnostic delay (Biesecker et al. 1993;
Stoller et al. 1994; Michie et al. 1996).
It is rare for close relatives not to know anything at
all about each other’s serious medical conditions, and
often they also know or have heard something when the
disease is hereditary. This may create uncertainty and
perhaps fear, especially if the knowledge is imprecise and
diluted with myth. This may be an important reason to
explain why tested relatives (e.g., M-, MZ-, and Z-
screened groups) had the highest percentages approving
proband’s disclosure of the identity of relatives (fig. 1),
and, furthermore, why tested relatives were most ready
to dispense with the need for the proband’s consent for
approaching relatives. In fact, relatives approved disclo-
sure of their own identity so that they could be informed
about their genetic risk. In the case of A1AD, the ma-
jority seemed to prefer to know their risk status and the
options for prevention of disease at the cost of a possible
violation of their privacy. This is in agreement with pre-
liminary results from studies of breast cancer (Winter et
al. 1996) and prostate cancer (Bratt et al. 1997), showing
high interest in testing and very few privacy concerns
among unaffected family members at risk.
The no-type group of relatives, who had not been
tested because they had not responded to the inquiry
from the Danish A1AD Register, were almost as skep-
tical as the control group about disclosure of the identity
of relatives (fig. 1). Although small, the between-group
differences in attitude toward these three questions on
disclosure of identities to health authorities may reflect
some selection bias between tested and nontested rela-
908 Am. J. Hum. Genet. 65:902–909, 1999
tives (fig. 1). It suggests that it was not simply a question
of laziness or “laissez faire” that relatives belonging to
the no-type group chose not to be tested.
In contrast to the probands, the relatives had the op-
tion of avoiding the outbreak of disease, in this case
pulmonary insufficiency. The options for prevention of
debilitating disease give a person at risk for A1AD such
important benefits that there is little reason to suppose
that such a person would not want the benefits of know-
ing the risk of A1AD. Therefore, respect for relatives’
right to autonomy (Wilcke 1998) confirms the view that
relatives should be informed about A1AD. This was in
agreement with the present result, in which as many as
39%–42% (fig. 3) indicated that the proband’s sister
ought to be informed, to enable her to decide for herself
whether she wanted to be tested. By contrast, only
1%–4% indicated that the proband’s sister ought not
to be informed, because they did not want to expose her
to knowledge she might not welcome (fig. 3). That only
1%–4% thought that a sister should not be informed is
in agreement with a study on hereditary hypercholes-
terolemia, in which 3% opposed such disclosure to rel-
atives (Andersen et al. 1998). Still, serious genetic risk
information may have a major negative impact (Winter
et al. 1996), and the situation in which a proband does
not want to inform his or her relatives must be carefully
considered, as noted in the ASHG Social Issues Subcom-
mittee on Familial Disclosure statement (1998).
The rather large number of participants and the ac-
ceptable response rate make selection bias unlikely. The
hypothetical nature of the questions must also be con-
sidered, but the responses to the questionnaire and,
again, the high response rate indicate that most partic-
ipants found the questions relevant and understandable.
In the Danish A1AD Register, 428 (85%) of 501 piZ
probands have disclosed identity of relatives. The re-
sponse rate among piZ groups (81%–90%) in the pre-
sent study is similar or higher, indicating an acceptable
response rate among registered piZ subjects without
known relatives.
In the letter of introduction, we decided from the be-
ginning not to mention liver disease, the second most
common health problem due to A1AD. This decision
was made so as not to divert participants’ attention from
the main issue of the questionnaire study—attitudes to-
ward family testing of the preventable lung disease due
to A1AD. Liver disease may lead to death in 1% of
newborn piZ persons (Sveger 1988), but, in adulthood,
death from liver disease (cirrhosis and carcinoma) is ex-
tremely rare (Eriksson et al. 1986). We believe that ex-
cluding liver disease from the discussion was necessary
and would not affect respondents’ attitudes.
In conclusion, the present data indicate that the ge-
netic counselor ought to ensure that relatives are prop-
erly informed about their risk of a severe genetic dis-
order, such as A1AD, where disability can be prevented
by a change of lifestyle or by careful management. Re-
sponses to the present questionnaire indicated some am-
bivalence even in affected families, and, consequently,
the physician must exercise a good deal of flexibility and
responsiveness to individual circumstances when asking
for relatives’ identity and when approaching relatives.
The findings also indicate that openness in affected fam-
ilies is an important goal; this means that, in most cases,
full information to all relatives about the disorder and
about who is ill seem essential for successful genetic
counseling.
References
American Society of Human Genetics Social Issues Subcom-
mittee on Familial Disclosure (1998) Professional disclosure
of familial genetic information. Am J Hum Genet 62:
474–483
Andersen LK, Jensen HK, Juul S, Færgeman O (1998) Attitude
of patients toward detection of hereditary disease: hetero-
zygote familial hypercholesterolaemia. Ugeskr Læger 160:
6075–6081
Benkendorf JL, Reutenauer JE, Hughes CA, Eads N, Willison
J, Powers M, Lerman C (1997) Patients’ attitude about au-
tonomy and confidentiality in genetic testing for breast-ovar-
ian cancer susceptibility. Am J Med Genet 73:296–303
Berg D, Hirsh HL (1980) Duty to recall. South Med J 73:
1041–1044
Biesecker BB, Boehnke M, Calzone C, Markel DS (1993) Ge-
netic counseling for families with inherited susceptibility to
breast and ovarian cancer. JAMA 269:1970–1980
Bloch M, Adam S, Wiggins S, Huggins M, Hayden MR (1992)
Predictive testing for Huntington’s disease in Canada: the
experience of those receiving an increased risk. Am J Med
Genet 42:499–507
Bratt O, Kristoffersson U, Lundgren R, Olsson H (1997) Sons
of men with prostate cancer: their attitudes regarding pos-
sible inheritance of prostate cancer, screening, and genetic
testing. Urology 50:360–365
Buist SA (1990) Alpha 1-antitrypsin deficiency—diagnosis,
treatment and control: identification of patients. Lung 168
Suppl:543–551
Bury M (1988) Meanings at risk: the experience of arthritis.
In: Anderson R, Bury M (eds) Living with chronic illness:
the experience of patients and their families. Unwin Hyman
Ltd., London
Caplan AL (1993) Neutrality is not morality: the ethics of
genetic counseling. In: de Gruyter A (ed) Our future: ethical
challenges in genetic counseling. New York, pp. 149–165
Eriksson S, Carlson Y, Velez R (1986) Risk of cirrhosis and
primary liver cancer in alpha 1-antitrypsin deficiency. N Engl
J Med 314:736–739
Hayes CV (1992) Genetic testing for Huntington’s disease—a
family issue. N Engl J Med 327:1449–1451
Hirsch HL (1975) Malpractice liability of physicians to third
parties. Case and Comment 82:44–45
Huggins M, Bloch M, Wiggins S, Adam S, Suchowersky O,
Trew M (1992) Predictive testing for Huntington’s disease
Wilcke et al.: Disclosing the Identity of Relatives 909
in Canada: adverse effects and unexpected results in those
receiving a decreased risk. Am J Med Genet 42:508—515
Larsson C (1978) Natural history and life expectancy in severe
alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand 204:
345–351
McAbee GN, Sherman J, Davidoff-Feldman B (1998) Physi-
cians duty to warn third parties about the risk of genetic
diseases. Pediatrics 102:140–142
McNeil TF, Harty B, Thelin T, Aspegren-Jansson E, Sveger T
(1986) Identifying children at high somatic risk: long term
effects on mother-child interaction. Acta Psychiatr Scand 74:
555–562
Merz JF, Cho MK, Sankar P (1998) Familial disclosure in
defiance of nonconsent. Am J Hum Genet 63:898–899
Michie S, McDonald V, Marteau T (1996) Understanding re-
sponses to predictive genetic testing: a grounded theory ap-
proach. Psychol Health 11:455–470
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman
K, Tavtigan S, Liu Q, et al (1994) A strong candidate for
the breast and ovarian cancer susceptibility gene BRCA1.
Science 266:66–71
Nielsen OH, Thomsen BL, Green NA, Andersen PK, Hauge
M, Schiøtz PO (1988) Cystic fibrosis in Denmark 1945–
1985: an analysis of incidence, mortality, and influence of
centralized treatment on survival. Acta Paediatr Scand 77:
836–841
Robinson I (1988) Reconstructing lives: negotiating the mean-
ing of multiple sclerosis. In: Anderson R, Bury M (eds) Liv-
ing with chronic illness: the experience of patients and their
families. Unwin Hyman Ltd, London
Seersholm NJ, Kok-Jensen A (1995) Survival in relation to
lung-function and smoking cessation in patients with severe
hereditary alpha1-antitrypsin deficiency. Am J Respir Crit
Care Med 151:369–373
Seersholm NJ, Kok-Jensen A, Dirksen A (1994) Survival of
patients with severe a1-antitrypsin deficiency with special
reference to non-index cases. Thorax 49:695–698
Stoller JK, Smith P, Yang P, Spray J (1994) Physical and social
impact of alpha 1-antitrypsin deficiency: results of a survey.
Cleve Clin J Med 61:461–467
Strauss AL, Corbin J, Fagerhaught S, Glaser BG, Maines D,
Suczek B, Wiener CL (1984) Chronic health and the quality
of life (2d ed). C. V. Mosby Company, St. Louis
Sveger T (1988) The natural history of liver disease in alpha
1-antitrypsin deficient children. Acta Paediatr Scand 77:
847–851
Thelin T, McNeil TF, Sveger T (1985) Identifying children at
high somatic risk (alpha 1 antitrypsin deficiency): possible
long-term effects on parents’ reproduction, marital status
and social class level. Acta Psychiatr Scand 71:636–643
Thomsen OØ, Wulff HR, Martin A, Singer PA (1993) What
do gastroenterologists in Europe tell cancer patients? Lancet
341:473–476
Tibben A, Freets PG, van de Kamp JJP, Niermeijer MF, Vegter
van der Vlis M, Roos RAC, van Ommen GJB, et al (1993)
Presymptomatic DNA-testing for Huntington’s disease: pre-
test attitudes and expectations of applicants and their part-
ners in the Dutch program. Am J Med Genet 48:10–16
Turk DC (1979) Factors influencing the adaptive process with
chronic illness. In: Sarason A, Spielberger CD (eds) Stress
and anxiety, vol 6:291–311. Halsted Press, Washington, DC
Wiggins S, Whyte P, Huggins M, Adam S, Theilmann J, Bloch
M (1992) The psychological consequences of predictive test-
ing for Huntington’s disease. N Engl J Med 327:1401–1405
Wilcke JTR (1998) Late onset genetic disease: where ignorance
is bliss, is it folly to inform relatives? BMJ 317:744–747
Winter PR, Wiesner GL, Finnegan J, Bartels D, LeRoy B, Ping-
Ling C, Sellers TA (1996) Notification of a family history
of breast cancer: issues of privacy and confidentiality. Am J
Med Genet 66:1–6
Wu MC, Eriksson S (1988) Lung function, smoking and sur-
vival in severe alpha 1-antitrypsin deficiency, PiZZ. J Clin
Epidemiol 41:1157–1165
